The promising preliminary clinical trials results indicating the efficacy of EISO therapies to manage inflammatory skin disorders together with the ability of EISO to decrease NF-κB activation by suppressing proinflammatory stimulation of PDE transcription, and directly suppressing PDE enzymatic activity, provides a strong rationale for continued study of EISO as a potential new therapeutic for the treatment of inflammatory skin conditions such as PS and AD. The gene discussed is NFKB1; the disease is inflammatory skin disease.